First Foundation Advisors Vertex Pharmaceuticals Inc Transaction History

First Foundation Advisors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 06, 2024	SELL	$392.81 - $485.53 $9,427 - $11,652	-24 Reduced 6.47%	347 $162,000
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $164,983 - $197,537	-481 Reduced 56.46%	371 $150,000
Q3 2023 Nov 15, 2023	SELL	$338.18 - $362.46 $36,861 - $39,508	-109 Reduced 11.34%	852 $296,000
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $34,586 - $38,710	110 Added 12.93%	961 $338,000
Q1 2023 May 12, 2023	BUY	$283.23 - $323.1 $2,549 - $2,907	9 Added 1.07%	851 $268,000
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $240,609 - $270,686	842 New	842 $243,000

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of First Foundation Advisors, based on Form 13F filings with the SEC.

Stay updated on First Foundation Advisors with notifications on news.